MMRGlobal receives cancer-fighting anti-CD20 monoclonal antibodies patent in ... Pharmaceutical Business Review This is the fourth country to issue this patent as a result of the Expedited Patent Allowance Program which follows the issuance of US patents to MMR for its anti-CD20 monoclonal antibodies. The South Korean patent will be issued under the title ... |
